Want to see HSCS full AI Analyst Report?
HSCS Stock Chart & Stats
$3.35
-$0.05(-1.44%)
At close: 4:00 PM EST
$3.35
-$0.05(-1.44%)
Day’s Range― - ―
52-Week Range$1.63 - $4.30
Previous CloseN/A
Volume8.49K
Average Volume (3M)58.86K
Market Cap
$8.85M
Enterprise Value$10.69
Total Cash (Recent Filing)$3.40B
Total Debt (Recent Filing)$3.87M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Jul 22, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.94
Shares Outstanding3,290,350
10 Day Avg. Volume93,774
30 Day Avg. Volume58,857
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.05
Price to Sales (P/S)757.08
P/FCF Ratio-0.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside258.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.1
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
FDA 510(k) Submission For MyoVista WavECGA completed 510(k) submission establishes a clear regulatory pathway for commercializing the MyoVista wavECG. FDA clearance would enable product market entry, recurring device sales and clinical adoption, changing the company’s revenue trajectory and strategic positioning over the medium term.
Expanded Equity Incentive CapacityIncreasing the equity incentive pool strengthens long-term talent retention and alignment with shareholders. For a small medical device company, expanded equity compensation helps recruit and retain critical clinical, regulatory and commercial talent needed to execute commercialization and scale operations reliably.
Positive TTM Equity And Sizable AssetsDespite capital structure stress, positive trailing-twelve-month equity and a sizable asset base provide a tangible balance-sheet foundation. That asset base supports continued regulatory/commercial efforts and gives potential collateral for financing or partnerships over the next several months.
Bears Say
Severe Operating Cash BurnVery large negative operating cash flow indicates the business cannot self-fund operations and will need repeated external financing. This creates ongoing dilution and solvency risk, constraining strategic options and increasing default risk if capital markets tighten over the medium term.
Minimal And Declining RevenueAn extremely small, volatile revenue base means core operations are not producing sustainable sales to cover fixed costs. Until commercial traction is achieved, margins and scalability remain theoretical, leaving the company reliant on funding rather than organic cash generation.
High Leverage Relative To EquityDebt materially exceeding equity signals elevated financial risk and interest burden. High leverage reduces flexibility to fund commercialization, raises refinancing risk, and can force adverse covenant or restructuring outcomes if operating losses persist over the next several quarters.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $1.63 and its highest was $4.30 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $8.85M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Jul 22, 2026 which is today.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Currently, no data Available
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 3,290,350 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
HSCS Stock 12 Month Forecast
Average Price Target
$12.00
▲(258.21% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
15.32% Insiders
1.28% Mutual Funds
0.58% Other Institutional Investors
82.28% Public Companies and
Individual Investors